Comparative Pharmacology
Head-to-head clinical analysis: KOMBIGLYZE XR versus SITAGLIPTIN PHOSPHATE AND METFORMIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KOMBIGLYZE XR versus SITAGLIPTIN PHOSPHATE AND METFORMIN HYDROCHLORIDE.
KOMBIGLYZE XR vs SITAGLIPTIN PHOSPHATE AND METFORMIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KOMBIGLYZE XR is a combination of saxagliptin, a DPP-4 inhibitor, and metformin, an AMPK activator. Saxagliptin increases incretin levels (GLP-1, GIP) by inhibiting DPP-4, leading to increased insulin release and decreased glucagon secretion. Metformin decreases hepatic gluconeogenesis and increases peripheral insulin sensitivity.
Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4), increasing endogenous incretin hormones (GLP-1, GIP) which enhance insulin secretion and decrease glucagon levels in a glucose-dependent manner. Metformin activates AMP-activated protein kinase (AMPK), decreasing hepatic glucose production and improving insulin sensitivity.
One tablet orally once daily with food; available strengths: saxagliptin 5 mg/metformin extended-release 500 mg, saxagliptin 5 mg/metformin extended-release 1000 mg. Titrate based on glycemic response and tolerability.
Initial dose based on current metformin dose: for patients not on metformin, start with sitagliptin 50 mg/metformin 500 mg PO BID; for metformin monotherapy, switch to sitagliptin 50 mg/metformin 500 mg or 1000 mg PO BID; for patients on sitagliptin, start with sitagliptin 50 mg/metformin 500 mg or 1000 mg PO BID. Maximum daily dose: sitagliptin 100 mg, metformin 2000 mg.
None Documented
None Documented
Terminal elimination half-life for saxagliptin is 2.5 hours and for its active metabolite is 3.1 hours; clinical context: no significant accumulation at steady state.
Sitagliptin: terminal t1/2 12.4 hours, allows once-daily dosing. Metformin: terminal t1/2 6.2 hours, accumulates with renal impairment.
Renal excretion of unchanged saxagliptin (24%) and its active metabolite 5-hydroxy saxagliptin (22%); fecal excretion of parent (0.3%) and metabolite (6%); total renal elimination accounts for approximately 75% of the administered dose.
Sitagliptin: 87% renal excretion as unchanged drug, 13% fecal (biliary). Metformin: 90% renal excretion as unchanged drug, 10% fecal.
Category C
Category A/B
DPP-4 Inhibitor + Biguanide Combination
DPP-4 Inhibitor